TrialESMO open2020

Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials.

Andrew X Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.